Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

<p>Abstract</p> <p>Background</p> <p>Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting...

Full description

Bibliographic Details
Main Authors:	Stickelmeyer Mary, Johnson Jason, Kothare Prajakti, Bergstrom Richard F, Detke Holland C, McDonnell David P, Sanchez-Felix Manuel V, Sorsaburu Sebastian, Mitchell Malcolm I
Format:	Article
Language:	English
Published:	BMC 2010-06-01
Series:	BMC Psychiatry
Online Access:	http://www.biomedcentral.com/1471-244X/10/45

Similar Items

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
by: Stefaniak Victoria J, et al.
Published: (2010-06-01)

Postinjection delirium/sedation syndrome with olanzapine depot injection
by: Sadhvi Mythili Sarangula, et al.
Published: (2016-01-01)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
by: Ascher-Svanum H, et al.
Published: (2014-06-01)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
by: Detke Holland C, et al.
Published: (2012-05-01)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
by: Stauffer Virginia L, et al.
Published: (2011-09-01)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
by: Ascher-Svanum H, et al.
Published: (2012-05-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-01-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-06-01)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
by: Rosaria Di Lorenzo, et al.
Published: (2010-09-01)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
by: Leslie Citrome
Published: (2009-11-01)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
by: Watson Susan B, et al.
Published: (2011-02-01)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
by: Anand E, et al.
Published: (2016-10-01)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
by: JP Lindenmayer
Published: (2010-05-01)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
by: An, et al.
Published: (2015-05-01)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
by: Peuskens Joseph, et al.
Published: (2012-08-01)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
by: Ciudad A, et al.
Published: (2013-11-01)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
by: Citrome L, et al.
Published: (2019-09-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
by: Katagiri H, et al.
Published: (2018-04-01)

An unusual complication of a long-acting injectable antipsychotic: deep venous thrombosis caused by olanzapine pamoate
by: Serhat Tunç, et al.
Published: (2018-04-01)

Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.
by: Robinson R, et al.
Published: (2003-01-01)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
by: Eduard Parellada, et al.
Published: (2012-01-01)

Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site
by: Candice M. Klingerman, et al.
Published: (2015-11-01)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
by: Suneeta James, et al.
Published: (2016-01-01)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
by: Natalia N. Petrova, et al.
Published: (2020-12-01)

Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Therapeutic Outcomes in Patients with Schizophrenia
by: Pei-Ting Kuo, et al.
Published: (2014)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
by: Rosa Catalán, et al.
Published: (2011-01-01)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
by: Rosa Catalán, et al.
Published: (2011-05-01)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
by: Borah Kim, et al.
Published: (2012-01-01)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
by: Louz&atilde; M, et al.
Published: (2011-06-01)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
by: Brasso C, et al.
Published: (2017-11-01)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
by: Dhiren Singh, et al.
Published: (2009-08-01)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
by: Suneeta James, et al.
Published: (2019-01-01)

INHALATION SEDATION IN THOSE WITH SEPSIS-ASSOCIATED DELIRIUM
by: N. A. Rezepov, et al.
Published: (2018-01-01)

The evaluations of risperidone and olanzapine in the treatment of schizophrenia disorders
by: Shu-Ling Chang, et al.
Published: (2010)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
by: Gloria Giordano, et al.
Published: (2020-01-01)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
by: Sugawara N, et al.
Published: (2019-01-01)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
by: Ludovic Samalin, et al.
Published: (2016-11-01)

Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
by: Tzanakaki Maria, et al.
Published: (2006-02-01)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
by: Pietrini F, et al.
Published: (2019-04-01)

Cannot write session to /tmp/vufind_sessions/sess_p82gph92plmn3vf42dhdpu4oma